Close
Help
Need Help?



Calls for Papers Updated

Posted Thu, Mar, 28,2013

We are pleased to announce that all calls for papers have been updated by the Editors in Chief and our editorial boards are ready for your submissions.We offer professional services to ensure that your publishing experience with us is a positive one:Fast and efficient processingHigh quality pair reviewOpen accessHigh visibility and extensive indexingOur services are recommended by your colleagues....

Continue Reading →

Posted in: Calls for Papers

Get answers in real time with Libertas live chat

Posted Tue, Mar, 26,2013

Receive answers to your questions in real time with Libertas live chat. Connect to all members of our team regardless of location and avoid delays that can occur in email communication.Libertas live chat works like an instant messaging service. From any Libertas webpage simply click on the “Need help?”  button, fill in the required information and start your chat.Efficiently recei...

Continue Reading →

Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration

Posted Tue, Mar, 26,2013

Published today in Clinical Medicine Insights: Therapeutics is a new review by Michael W. Stewart.  Read more about this paper below:TitleReview of Aflibercept for the Treatment of Neovascular Age-Related Macular DegenerationAbstractThe treatment of exudative age-related macular degeneration (AMD) has been completely transformed by the development of drugs that bind vascular endothelial growt...

Continue Reading →

Posted in: Articles Published

Follow Libertas on Twitter

Posted Thu, Mar, 21,2013

Follow @la_press and stay up to date with the latest medical and scientific articles with ease. With 40 different category feeds and a selection of news feeds @la_press allows you to receive timely announcements of both new and forthcoming articles.Receive updates on newly published papers, journal developments and calls for papers directly to your news stream. Missed an article? We have you cover...

Continue Reading →

Posted in: Social Media

Safety and Efficacy of Fidaxomicin

Posted Thu, Mar, 21,2013

Published today in Clinical Medicine Insights: Therapeutics is a new review by Monica A. Donnelley, Jeremiah J. Duby, and Christine S. Cocanour.  Read more about this paper below:TitleSafety and Efficacy of Fidaxomicin in Patients With Clostridium Difficile InfectionAbstractFidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in ...

Continue Reading →

Posted in: Articles Published

Published This Week (18 March to 22 March)

Posted Thu, Mar, 21,2013

We are pleased to announce the publication of the following peer reviewed papers. Sign up to receive email alerts to receive immediate notification of new papers. Air, Soil and Water Research Geothermal Dynamics in Vochysia Divergens Forest in a Brazilian WetlandBioinformatics and Biology InsightsKnowledge Discovery in Variant Databases Using Inductive Logic Programming Breast Cancer: Basic and Cl...

Continue Reading →

Posted in: Articles Published

Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Libertas Academica
testimonial_image
I would like to extend my gratitude for creating the next generation of a scientific journal -- the science journal of tomorrow. The entire process bespoke of exceptional efficiency, celerity, professionalism, competency, and service.
Dr Jason B. Nikas (Medical School University of Minnesota, Minneapolis, MN, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results